The European Commission (EC) has granted marketing authorisation for global healthcare company Fresenius Kabi’s first adalimumab biosimilar, IDACIO®.
The medical technology was developed by Fresenius Kabi to support specialists in the fields of rheumatology, gastroenterology and dermatology. Specifically, the IDACIO® was created to treat patients with rheumatoid arthritis, plaque psoriasis, adult and paediatric Crohn’s disease and ulcerative colitis amongst a number of other conditions.
Dr Michael Schönhofen, president of the pharmaceuticals and devices division, and member of the Fresenius Kabi management board, said: "Fresenius Kabi has a heritage of providing high-quality and affordable products to patients and the EC approval of IDACIO® is an exciting achievement for us, leading to our first entry into the European biosimilars market.
"We are devoted to putting patients first, and we will focus our efforts to ensure patients access to IDACIO® within Europe."
The approval of IDACIO® by the European Commission allows Fresenius Kabi to boost its portfolio of biosimilars to bring about a focus on autoimmune and oncology medicines. Not only is this milestone important for the patients who receive the treatments available as a result of the approval, but it also facilitates growth amongst the company, enabling it to expand its services across Europe to bring affordable treatment options to those in need across the continent.